Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rapid Dose Therapeutics Corp C.DOSE

Alternate Symbol(s):  RDTCF

Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. It provides disruptive drug delivery technologies designed to improve patient outcomes. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. It has one operating segment comprising production, distribution, research, and the provision of technical services for the delivery of oral thin film strips containing active ingredients. It offers over-the-counter and pharmaceutical drug delivery solutions. Its QuickStrip Energy delivers energizing caffeine. Its QuickStrip B12 delivers vitamin B12 to the system, assisting with metabolism and physical energy. Its QuickStrip Sleep delivers melatonin to the system, inducing natural and healthy sleep. QuickStrip Lidocaine is its dental product.


CSE:DOSE - Post by User

Post by lscfaon Jan 30, 2023 11:34am
201 Views
Post# 35254046

Fins on sedar

Fins on sedarOn October 10 2020, the Company received its site licence for Natural Health Products approved for manufacturing, packaging and labelling of natural health products. Importing, under that Licence, required the submission of additional requested documents from the manufacturer. This re-submission process continued throughout 2021 and 2022, in part due to extensive delays in Health Canada’s approval processes due to approving products required to combat the COVID-19 epidemic. Products imported by the Company during the extended approval process contained the necessary natural health product numbers (NPNs) assigned by Health Canada and were processed through Customs’ normal channels accordingly. On January 5, 2023 Health Canada and the Company mutually agreed to the withdrawal of the previously approved site licence and submission a new site licence application including “importing” as an additional permitted activity as the fastest route to approval. The Company submitted this application on January 20, 2023 and according to Health Canada, service standards, expects the complete site license to be issued within 30 days. While the Company believes it will successfully obtain the site license, there is no assurance the application as filed will be approved. During the interim period between the revised application resubmission and receipt of the license, the Company is permitted and continues to carry on licensable activities in its cannabis licensed operations. The Company believes any economic impact on account of not carrying on nutraceutical product activities during such period will be minimal and have no material impact on the operations of the business.


<< Previous
Bullboard Posts
Next >>